NCT06649877

MK-6194 Site of Injection Study in Healthy Adult Participants (MK-6194-013)

A Randomized Clinical Study to Evaluate the Impact of Injection Site (Thigh vs Abdomen) on the Pharmacokinetics and Relative Bioavailability of Subcutaneously Injected MK-6194 in Healthy Adult Participants

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 16 (actual)
• Sponsor: Merck Sharp & Dohme LLC · Industry
• Sex: All
• Age: 18 Years – 50 Years
• Healthy volunteers: Accepted

Summary

The goal of this study is to learn what happens to MK-6194 in a healthy person's body when different injection sites are used. Researchers will compare what happens to MK-6194 in a healthy person's body when it is injected into the abdomen and when it is injected into the thigh. Researchers think that the average amount of MK-6194 in a person's body over time will be similar when injected into the thigh or abdomen. They also want to learn if it is safe to inject MK-6194 into the abdomen and thigh, and if people tolerate it.

Conditions

• Healthy

Interventions

Type	Name	Description
BIOLOGICAL	MK-6194	single injected dose

Timeline

• Start date: 2023-03-20
• Primary completion: 2023-07-13
• Completion: 2023-07-13
• First posted: 2024-10-21
• Last updated: 2024-10-21

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study